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The placebo effect has evolved from being thought of as a nuisance in clinical research to
a biological phenomenon worthy of scientific investigation. The study of the placebo
effect and of its evil twin, the nocebo effect, is basically the study of the therapeutic
ritual around the patient, and it plays a crucial role in the therapeutic outcome. In recent
years, different types of placebo responses have been analyzed with sophisticated biolog-
ical tools that have uncovered specific mechanisms at the neuroanatomical, neuro-
physiological, biochemical, and cellular levels. Most of our knowledge about the
neurobiological mechanisms of the placebo response comes from pain and Parkinson’s
disease, whereby the neuronal networks involved in placebo responsiveness have been
identified. In the first case, opioid, cannabinoid, and cholecystokinin circuits have been
found to be involved. In the second case, dopaminergic activation in the striatum and
neuronal changes in basal ganglia have been described. This recent research has revealed
that these placebo-induced biochemical and cellular changes in a patient’s brain are very
similar to those induced by drugs. This new way of thinking may have profound implica-
tions in clinical trials and medical practice both for pharmacological interventions and for
nonpharmacological treatments such as acupuncture.1. Introduction
Any pharmacological or nonpharmacological treatment has
two components, one related to the specific effects of theersity of Turin Medical School, Co
t
acopuncture Institutetreatment itself and the other related to the perception
that the therapy is being administered [1]. The latter is
called placebo effect or placebo response. Placebo is the
Latin word of “I shall please.” The study of the placeborso Raffaello 30, 10125 Turin, Italy.
98 F. Benedettieffect is basically the analysis of the relationship between
the complex psychosocial context surrounding the patient,
which constitutes the ritual of the therapeutic act, and its
effects on the patient’s brain [2,3]. Two terms are
commonly encountered in placebo literature: placebo
effect and placebo response. Although they are often used
interchangeably, technically they refer to different
concepts. The placebo effect is that observed in the placebo
arm of a clinical trial, and is produced by the placebo
psychobiological phenomenon in addition to other factors,
such as spontaneous remission, regression to the mean,
biases, and judgment errors. The placebo response, on the
other hand, designates the psychobiological phenomenon in
isolation, and can best be studied in specifically designed
experimental protocols. The definition of nocebo effect also
needs to be stated precisely. The term nocebo (Latin for “I
shall harm”) is the result of negative expectations, in
contrast to the placebo effect, which is related to positive
expectations. Moerman [4] has proposed to substitute the
term placebo response with meaning response, to under-
score the importance of the patient’s beliefs about the
treatment. At the limit, a physical substance or treatment
needs not be administered at alldthat is, a placebo/nocebo
effect can also be induced by raising expectations in the
complete absence of a treatment, just by inducing expec-
tations. These effects are sometimes called “placebo/
nocebo-related” effects [5].Figure 1 The neurobiological mechanisms of the placebo
effect are better understood in pain and Parkinson’s disease. In
pain, either endogenous opioids or endocannabinoids can be
activated, depending on the previous exposure to opioid or
non-opioid drugs, respectively. Cholecystokinin (CCK) antago-
nizes the action of opioids. In Parkinson’s disease, a release
of dopamine takes place in the striatum after placebo
administration.2. Psychological mechanisms
Different explanatory mechanisms have been proposed for
both placebo and nocebo effects, each supported by
experimental evidence. They need not be mutually exclu-
sive and can actually be at work simultaneously. The first
theory considers the placebo effect as an example of
classical conditioning. As described in the studies on
conditioned reflexes by the Russian physiologist Ivan Pav-
lov, the repeated co-occurrence of an unconditioned
response to an unconditioned stimulus (e.g., salivation
after the sight of food) with a conditioned stimulus (e.g.,
a bell ringing) induces a conditioned response (i.e., sali-
vation that is induced by bell ringing alone). Likewise,
aspects of the clinical setting (e.g., color, taste, shape of
a pill, as well as concurrent aspects of the therapeutic
environment, such as white coats or the peculiar hospital
smell) can also act as conditioned stimuli, eliciting a ther-
apeutic response in the absence of an active principle, just
because they have been paired with it in the past [6e9].
Similarly, the conditioned response can also occur for
a nocebo effect. For example, nausea can be elicited by
the sight of the environment where chemotherapy has been
administered in the past.
The second explanation centers on expectations,
generated as the product of cognitive engagement, when
the patient consciously foresees a positive/negative
outcome, based on factors such as verbal instructions,
environmental clues, emotional arousal, previous experi-
ence, and the interaction with care-providers. By grading
the degree of expectation, graded responses can be
obtained: the same placebo cream applied onto three
contiguous skin areas induces a progressively strongeranalgesia, according to the strength of the accompanying
words (“it is a powerful/weak analgesic cream”) [10]. This
is true also in the clinical setting, where changing the
symbolic meaning of a basal physiological infusion in post-
operative patients resulted in different additional pain-
killer request [11]. The expectation of forthcoming pain can
be further modulated by a number of emotional and
cognitive factors, like desire and self-efficacy [12]. A
related proposed mechanism posits that anxiety reduction
also plays a role in placebo responses, because the subject
interpretation of ambiguous sensations is turned from
harmful and threatening to benign and unworthy of atten-
tion. Accordingly, Vase and collaborators [13] found
decreased anxiety levels in patients with irritable bowel
syndrome who received a placebo treatment.
A particular type of expectation which has been sug-
gested as a contributor to the genesis of placebo effects is
the expectation of reward. Our brain is endowed with a so-
called reward system, whichdthrough the activation of the
mesolimbic and mesocortical pathways and the release of
dopaminedfulfills its natural task to provide pleasurable
feelings in response to life sustaining functions, such as
eating, drinking, or sex, in order to encourage repetition of
those functions. It has been argued that placebos have
reward properties, associated with the beneficial outcome
they provide. In other words, the expected clinical benefit is
a form of reward, which triggers the placebo response [14].3. Biological mechanisms in pain
The past decade has witnessed the beginning of clarifica-
tion of neurochemical and pharmacological details of
placebo analgesia (Fig. 1). There is now compelling
evidence that the secretion of endogenous opioids in the
brain is the key event in placebo pain modulation [15].
Placebo responders had levels of b-endorphin in the
How therapeutic rituals affect the patient’s brain 99cerebrospinal fluid which were more than double those of
nonresponders; opioids released by a placebo procedure
displayed the same side effects as exogenous opiates;
naloxone-sensitive cardiac effects could be observed during
placebo-induced expectation of analgesia. Indirect support
also came from the placebo-potentiating role of the cole-
cystokinin (CCK) antagonist proglumide. In fact, the CCK
system effects counteract those of opioids, delineating
a picture where the placebo effect seems to be under the
opposing influence of facilitating opioids and inhibiting CCK
[15]. In some situations, however, a placebo effect can still
occur after blockade of opioid mechanisms by naloxone,
indicating that systems other than opioids are also impli-
cated. For example, with a morphine conditioning and/or
expectation-inducing protocol, naloxone was able to
completely reverse placebo analgesia induced in experi-
mental ischemic arm pain. Conversely, with the use of
ketorolac (a nonopioid analgesic) in the same protocol,
naloxone was ineffective, whereas the CB1 cannabinoid
receptor antagonist rimonabant completely blocked
placebo analgesia [16]. These results indicate that both
opioid and cannabinoid mechanisms are involved in the
placebo analgesic response, depending on the drug (either
opioid or nonopioid) which was used in the preconditioning
phase.
A positron emission tomography (PET) study showed
overlapping in the brain activation pattern generated by
opioid-induced analgesia (by the m-agonist remifentanil) and
by placebo-induced analgesia [17]. Common activated areas
included the rostral anterior cingulate cortex and the orbi-
tofrontal cortex. Direct demonstration of endogenous opioid
release was obtained through [11C]carfentanil displacement
by the activation of opioid neurotransmission, with the
decrease in binding correlating with placebo reduction of
pain intensity reports. Recently, naloxone was observed to
block placebo-induced responses in pain modulatory
cortical structures and in key structures of the descending
pain control system [18]. For a review on neuroimaging
studies, see the report of Zubieta and Stohler [19].
Interestingly, the areas involved in placebo analgesia,
including those related to placebo acupuncture, are part of
a general circuit underlying the voluntary regulation of
affective responses (see [20e22]). In this direction, both
placebo analgesia [17,23,24] and emotional regulation [25]
are associated with increased activation in a modulatory
network that includes the rostral anterior cingulate cortex
and the ventrolateral prefrontal cortex. This suggests
a functionaleanatomical relationship between placebo
analgesia and emotional regulation in which topedown
modulation of the pain or emotional network is imple-
mented. This is particularly well studied in placebo
acupuncture studies [21,22].4. The nocebo hyperalgesic effect
Compared to placebo effect research, the investigation of
the nocebo effect raises more ethical difficulties, espe-
cially in the clinical setting. However, in recent times a few
experimental studies have begun to shed light on this
phenomenon, focusing mainly on the model of nocebo
hyperalgesia. In the protocols used, an inert treatment isgiven along with verbal suggestions of pain worsening,
resulting in exacerbation of pain. It has been suggested that
the anticipatory anxiety about the impending pain, brought
about by negative expectations, triggers the activation of
CCK, which in turn facilitates pain transmission and results
in hyperalgesia. Accordingly, this hyperalgesia can be
blocked by proglumide, a nonspecific CCK-1 and CCK-2
antagonist, in a dose-dependent manner. The proglumide
block is related specifically to nocebo/anxiety-induced
hyperalgesia rather than to the more general process of
nocebo-induced anxiety, as it is selectively exerted
on nocebo hyperalgesia but not on the concurrent
stress-induced hypothalamicepituitaryeadrenal axis
hyperactivity.
As noted before, proglumide also exhibited placebo-
potentiating effects, raising the question of how the two
endogenous systems, CCK and opioids, may interact in
producing negative or positive outcomes. It can be specu-
lated that the placeboenocebo phenomenon is
a continuum, with opioid and CCK-ergic systems acting as
the mediators of opposing effects.
As for placebo analgesia, neuroimaging techniques have
also brought important contributions to the knowledge of
nocebo hyperalgesia [26]. Here, again, expectations
without the physical administration of a nocebo treatment
have sometimes been exploited (“nocebo-like” effects).
Inducing negative expectations resulted in both amplified
unpleasantness of innocuous stimuli as assessed by
psychophysical pain measures (subject report) and
increased functional magnetic resonance imaging responses
in ACC, insula, hypothalamus, secondary somatosensory
areas, and prefrontal cortex. From these studies, it appears
that the circuitry underlying nocebo hyperalgesia largely
involves, with opposite modulation, the same areas
engaged by placebo analgesia [5].5. Parkinson’s disease
The neurobiological mechanisms of placebos have also been
studied in conditions other than pain. Parkinson’s disease is
particularly interesting because different approaches,
ranging from PET to micromapping methods (micro-
recording and microstimulation), have significantly
increased the body of knowledge of the placebo effect.
By using PET imaging, de la Fuente-Ferna´ndez and
colleagues [27,28] detected a significant drop in [11C]
raclopride binding potential when Parkinson patients were
injected with a saline solution along with the suggestion of
motor improvement. A reduction in [11C]raclopride binding
is indicative of an increase in extracellular dopamine
concentration. In the studies by de la Fuente-Ferna´ndez
et al [27,28], it occurred in the dorsal and ventral striatum
(Fig. 1). As the patients who experienced symptomatic
benefit released more dopamine in the dorsal striatum than
those who did not, the degree of placebo-induced dopa-
mine release in the dorsal striatum seems to be related to
the degree of perceived improvement by the patient [27].
Conversely, the level of placebo-dopamine release in the
ventral striatum is independent of perception of clinical
benefit [28]. As the ventral striatum (NAc) is involved in the
circuitry of reward mechanisms, de la Fuente-Ferna´ndez
100 F. Benedettiet al [27,28] suggested that placebo-induced dopamine
release might be related to expectation of reward. In the
case of the placebo effect, the reward would be the clinical
improvement. These results have been confirmed by
subsequent studies [29].
The subthalamic nucleus (STN) is now the major target
in the surgical therapy of Parkinson’s disease, and its
identification can require the recording of intranuclear
electrical activity. The possibility of studying patients with
Parkinson’s disease who are implanted with electrodes for
deep brain stimulation has been exploited to record from
single neurons after the administration of a placebo. Ben-
edetti et al [30] investigated for the first time the placebo
effect at the level of single neurons. These authors recor-
ded the activity from single neurons in the STN before and
after placebo administration to test whether neuronal
changes were linked to the clinical placebo response. Those
patients who showed a clear-cut clinical placebo
responsedas assessed by means of both the decrease in
arm rigidity and the subjective report of well-beingdalso
showed a significant decrease in neuronal discharge
compared to the pre-placebo condition. None of the
placebo nonresponders showed these differences. Bene-
detti et al [30] also found that the STN neurons of all the
placebo responders shifted significantly from a pattern of
bursting activity to a pattern of non-bursting discharge.
None of the placebo nonresponders showed any difference
in the number of bursting neurons before and after placeboFigure 2 Single neuron recording from a thalamic neuron before a
increase in firing rate following placebo administration, which is cinjection. Neuronal activity changes were also found in the
substantia nigra pars reticulata and in the thalamus [31]
(Fig. 2).
Indeed, several studies have reported apomorphine-
induced changes in the STN firing pattern of patients with
PD [32,33]. Although Levy et al [32] found a certain vari-
ability on the firing rates of single neurons under the effect
of apomorphine, Stefani et al [33] reported that the
administration of apomorphine is invariably followed by
reduction of firing activity from 40.4 to 27.2 Hz. Similarly,
in the study of Benedetti et al [30,31], a reduction of firing
rate was induced by a placebo.6. Depression
The neural mechanisms of placebo treatments have also
been studied in psychiatric disorders, such as depression
and drug addiction, although only a few pieces of infor-
mation are available in this case. There is a clear expla-
nation for this. Unlike single-dose trials of an intervention,
such as oral or intravenous analgesia or anti-Parkinson
acute therapy studies, antidepressants do not work
acutely, requiring on average a minimum of 2e3 weeks to
see clinical effects. Therefore, investigating placebo
effects in depression is more problematic from both an
ethical and a methodological point of view. In fact, if one
wants to see what happens in the patient’s brain viand after placebo administration in Parkinson patients. Note the
orrelated to clinical improvement.
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patient for a long period or, otherwise, to devise pre- and
post-treatment assessment with adequate control groups.
Of course, if one wants to compare a placebo group with
a no-treatment group to rule out spontaneous remission,
this requires that some patients should not be treated for
a long period, with the inherent ethical problems and
limitations. This is one of the main reasons why depression,
albeit an interesting and exciting model to study placebo
effects, has not been investigated in detail so far.
Depressed patients who undergo a placebo treatment
have been found to show both electrical and metabolic
changes in the brain. Placebos induced electroencephalo-
gram changes in the prefrontal cortex of patients with major
depression, particularly in the right hemisphere. In fact,
Leuchter et al [34,35] found distinct neurophysiological
patterns in the placebo responders behind the prefrontal
region by using an offline elaboration of electroencephalo-
gram recordings, labeled cordance. By using PET, changes in
brain glucose metabolism have also been documented in
patientswith unipolar depression [36]. Compared to baseline
patterns, patients treated with drug (fluoxetine), regardless
of response, showed changes in subcortical areas, including
the brainstem, hippocampus, and cortical regions, including
the posterior cingulate, the dorsolateral prefrontal cortex
(DLPFC), the premotor cortex, the dorsal anterior cingulate
cortex, and the inferior parietal posterior cortex. It was
possible to note a suppression of activity in the subgenual
cingulate (area 25). The placebo responders showed similar
activity patterns in the cortex as compared to the drug
responders, but the magnitude of change was smaller in
patients who received placebo.7. Drug addiction
Another example of the powerful role of expectation in
drug responses is the work by Volkow et al [37,38], who
investigated the effect of placebos in both cocaine abusers
and non-drug-abusing individuals. In particular, they
described the effects of methylphenidate on brain glucose
metabolism, as measured by [18F]deoxyglucose-PET, when
participants expected (1) to receive the drug and indeed
received the drug; (2) to receive the drug but they received
the placebo; (3) to receive placebo but they received the
drug; (4) to receive placebo and indeed received placebo.
The researchers found that when the participants expected
to receive drug, the effects were about 50% greater than
when the participants did not expect the drug. In other
words, unexpected methylphenidate induced smaller
changes in the thalamic and cerebellar metabolism, thus
indicating that expectation potentiates the pharmacolog-
ical action of methylphenidate [37]. In non-drug-abusing
participants, the changes in brain glucose metabolism
occurred in regions involved in emotional reactivity and
reward, such as the ventral gyrus (BA 25) and NAc [38]. The
different findings in cocaine abusers and non-cocaine
abusers suggest that in the first case, the enhanced
thalamic and cerebellar responses reflect conditioned
responses, whereas the changes in the striatum observed in
the non drug-abusing participants may indicate the preva-
lence of expectations in the absence of prior experience.8. Implications for clinical practice
The administration of placebos is widespread all over the
world, as demonstrated by the high percentage of physi-
cians surveyed who reported the use of placebo, usually to
calm patients, avert requests for unnecessary medication,
or as a supplemental treatment [39,40]. Deception is not
necessarily involved in the use of a placebo, and this can
represent an effective treatment which it would be
unethical to withdraw [41,42]. There is also ample space
for placebo use in less direct ways. For example, the
therapeutic environment is a complex context, in which
the active principle contained in a drug is not the sole
agent acting on the patient body. In fact, any treatment
administered in routine health care can be regarded as
having two components: one pharmacodynamic, the other
psychosocial. As described throughout this chapter,
expectations have a central role in determining this
second component (placebo or nocebo), and as they can
be elicited by any aspect of the therapeutic context, it is
in its optimization that the knowledge on placebo/nocebo
mechanisms can both fruitfully and ethically be applied.
To the extreme, total elimination of the context-induced
expectations can be achieved with hidden drug adminis-
tration carried out by a machine unbeknownst to the
patient. In this case, dose requirements for the achieve-
ment of a given level of analgesia are invariably higher
than in the open condition [43].
The first and foremost aspect of the psychosocial
context is the patienteprovider interaction. Indeed, the
placebo effect has recently been defined as a form of
interpersonal healing [44]. A list of eight specific clinical
actions has been proposed: speak positively about treat-
ments, provide encouragement, develop trust, provide
reassurance, support relationships, respect uniqueness,
explore values, and create ceremony [45]. Moreover,
nonverbal clues intentionally or unintentionally conveyed
by the therapist are important [46]. Equal attention should
be paid to avoid nocebo suggestions [47,48]. Language
incorporating negative suggestions should be changed to
offer positive hints (e.g., from “Here’s your pain medicine”
to “Here’s some medicine to help you get better”), in order
to minimize anxiety [49,50].
Another important aspect is what the context can teach
us about other patients’ experiences. Just by watching
others, it is possible to obtain useful information (the so-
called social observational learning). Just like other forms
of learning (prior experience, conditioning, expectation
induced by verbal communication), social observational
learning can also induce placebo/nocebo responses [51].
9. Implications for clinical trials
In clinical trials, the desired goal is just the opposite as in
clinical practice, namely, to limit and reduce placebo
effects as much as possible, in order to isolate the specific
effect of the active principle under scrutiny. Research on
placebo mechanisms has at least two important implica-
tions for clinical trials: (1) The design of protocols that
circumvent the need of a placebo arm. An example is the
“open/hidden” protocol, where the placebo component
102 F. Benedettistands out as the difference between overt or covert drug
administration, with no patients receiving sham treatment.
(2) The reevaluation of clinical trial methodology. In fact,
patient expectations are not usually among the controlled
variables but they have the potential to differentially
influence improvement in both control (placebo) and drug
arms, thus invalidating the attempt at separating the
pharmacodynamic effect. For example, a study on
acupuncture has showed that results could be drastically
reversed by redistributing the participants according to
what they believed was their group of assignment. In other
words, no differences were found with the standard
grouping, but the participants expecting real acupuncture
reported significant less pain than those believing to be in
the sham group, regardless of the real assignment [52].
Similar results were obtained in another study [53].
The large numbers of randomized controlled clinical
trials have drawn the attention of some authors to the need
to improve the design of such trials [54e56]. In particular,
adequate methodology is a critical issue in their planning
and execution, as different methodological approaches can
translate into different results. The side effects observed in
both the active medication arm and the placebo arm are
often influenced by nonspecific factors. This issue can be
quantified by using a systematic review approach to study
the rates of adverse events reported in the placebo arms of
clinical trials [57,58]. The participants recruited to take
part in a typical randomized, double-blind clinical trial
know they will receive either an active medication or
a placebo, and they are informed about the possible
adverse events they may experience. This information is
provided in the informed consent form and in the instruc-
tions given by the investigator. Informing the participants
about the possible adverse events they may experience has
a significant impact on their expectations. In particular, an
expectation of negative symptoms, in terms of adverse
effects, may be considered an important element in elic-
iting negative outcomes [57]. These nocebo phenomena
may help us better understand the occurrence of psycho-
logically driven adverse symptoms, as well as to improve
clinical trial designs and patienteprovider communication.
Therefore, understanding the placebo effect, its bio-
logical underpinnings and its use in clinical trials, repre-
sents a scientific challenge which not only will give insights
into human biology, but it will also generate new designs
and interpretations of the clinical trials that are currently
carried out [59,60].Acknowledgments
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